Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-25T12:36:51.827Z Has data issue: false hasContentIssue false
  • English
  • Français

Low CSF Concentrations of Cyclic GMP in Schizophrenia

Published online by Cambridge University Press:  29 January 2018

W. F. Gattaz ,
H. Cramer  and
H. Beckmann
W. F. Gattaz*
Affiliation:
Faculdade de Medicina da Fundacao do ABC (Brazil) and Visiting Professor, Central Institute of Mental Health, Mannheim, F.R. Germany
H. Cramer
Affiliation:
Department of Neurology, University of Freiburg, F.R. Germany
H. Beckmann
Affiliation:
The Central Institute of Mental Health—Mannheim, F.R. Germany
*
∗Correspondence and reprint requests: R. Leoncio de Carvalho 254 04003 Sao Paulo-S.P.-Brazil.
Get access Rights & Permissions [Opens in a new window]

Summary

Increasing evidence suggests that the concentrations of cyclic guanosine 3′5′-monophosphate (cGMP) in the cerebrospinal fluid (CSF) may reflect central cholinergic activity. When the concentrations of this nucleotide in the CSF from 28 schizophrenic patients (13 without and 15 with neuroleptic treatment) and 16 psychiatrically healthy controls was determined the schizophrenics showed significantly lower CSF levels of cGMP as compared to controls.

As dopamine and homovanillic acid concentrations were not altered in these CSF samples, this finding of reduced cGMP suggests a cholinergic-dopaminergic imbalance in schizophrenia, with a reduction of the former and consequently a relative dominance of the latter.

Type
Papers
Information
The British Journal of Psychiatry , Volume 142 , Issue 3 , March 1983 , pp. 288 - 291
Copyright
Copyright © 1983 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andén, N. E. & Bedard, P. (1971) Influence of cholinergic mechanisms on the function and turnover of brain dopamine. Journal of Pharmacy and Pharmacology, 23, 460–2.Google Scholar
Barbeau, A. (1962) Pathogenesis of Parkinson's disease: a new hypothesis. Canadian Medical Association Journal, 87, 802–7.Google Scholar
Barbeau, A. (1976) Parkinson's disease: etiological considerations. In The Basal Ganglia (ed. M. D. Yahr). New York: Raven Press, New York, pp 281–92.Google Scholar
Bartholini, G., Stadler, H. & Lloyd, K. C. (1973) Cholinergic-dopaminergic interactions in the extrapyramidal system. Advances in Neurology, 3, 233–41.Google Scholar
Beckmann, H., Riederer, P., Reynolds, G. & Gattaz, W. F. (1982) Phenylethylamine and phenylacetic acid in the CSF of schizophrenic patients and healthy controls. Archiv für Psychiatrie und Nervenkrankheiten (in press).Google Scholar
Cailla, H. L., Vannier, C. J. & Delaage, M. A. (1976) Guanosine 3'5'-cyclic monophosphate assay at the 10-15 mole level. Analytical Biochemestry, 70, 195–202.CrossRefGoogle Scholar
Ebstein, R. P., Biederman, J., Rimon, R., Zohar, J. & Belmaker, R. J. (1976) Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. Psychopharmacology, 51, 71–4.Google Scholar
Gattaz, W. F., Riederer, P., Reynolds, G., Gattaz, D. & Beckmann, H. (1982) Dopamine and noradrenaline in the cerebrospinal fluid of schizophrenic patients. Psychiatry Research (in press).Google Scholar
Gattaz, W. F., Waldmeier, P. & Beckmann, H. (1982a) CSF monoamine metabolites in schizophrenic patients. Acta Psychiatrica Scandinavica, 66, 350–60.CrossRefGoogle ScholarPubMed
Guyenet, P. G., Javoy, F., Agid, Y., Beaujouan, J. C. & Glowinski, J. (1975) Dopamine receptors and cholinergic neurons in the rat striatum. Advances in Neurology, 9, 43–51.Google Scholar
Ladinsky, H., Consolo, S., Bianchi, S., Samanin, R. & Ghezzi, D. (1975) Cholinergic-dopaminergic interaction in the striatum: the effect of 6-hydroxydopamine or pimozide treatment on the increased striatal acetylcholine levels induced by apomorphine, piribedil and d-amphetamine. Brain Research, 84, 221–6.CrossRefGoogle ScholarPubMed
McGeer, E. G., Fibiger, H. C., McGeer, P. L. & Brooke, S. (1973) Temporal changes in amine synthesizing enzymes of rat extrapyramidal structures after hemitransection or 6-hydroxydopamine administration. Brain Research, 52, 289–350.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The brief psychiatric rating scale. Psychological Reports, 10, 799–812.Google Scholar
Post, R. M. & Goodwin, F. K. (1978) Approaches to brain amines in psychiatric patients: a reevaluation of cerebrospinal fluid studies. In Handbook of Psychopharmacology (eds. L. L. Iversen, S. D. Iversen and S. H. Snyder). Vol 13. New York: Plenum Press, pp. 147–84.Google Scholar
Schindler, H., Maier, P., Schröter, E. & Cramer, H. (1981) Calcium-dependent accumulation induced by carbamylcholine of guanosine 3'5'-monophosphate in rabbit choroid plexus. Cell Calcium, 2, 225–33.Google Scholar
Smith, C. C., Tallman, J. F. & Post, R. M. (1976) An examination of baseline and drug induced levels of cyclic nucleotides in the cerebrospinal fluid of controls and psychiatric patients. Life Sciences, 19, 131–6.CrossRefGoogle ScholarPubMed
Spitzer, R. L., Endicott, J. & Robins, E. (1975) Research Diagnostic Criteria. Instrument no. 58. New York: New York Psychiatric Institute.Google Scholar
Stadler, H., Lloyd, K. G., Gadea-Ciria, M. & Bartholini, G. (1973) Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine. Brain Research, 55, 476–80.Google Scholar
Trabucchi, M., Cheney, D. L., Racagni, G. & Costa, E. (1974) Involvement of brain cholinergic mechanisms in the action of chlorpromazine. Nature (London), 249, 664–6.Google Scholar
Trabucchi, M., Cheney, D. L., Racagni, G. & Costa, E. (1975) In vivo inhibition of striatal acetylcholine turnover by L-DOPA, apomorphine and (+)-amphetamine. Brain Research, 85, 130–4.Google Scholar
Zimmer, R., Teelken, A. W., Cramer, H., Ackenheil, M., Zandler, K. J., & Fischer, H. (1980) Short- and long-term effects on GABA and dopamine neurones during treatment with sulpiride. Adv. Biochem. Psychopharmacol, 24, 537–9.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.